Talus Bioscience, a cutting-edge biotechnology startup based in Seattle, WA, is thrilled to announce that it has successfully raised $25,500,000 in its latest funding round. Founded in September 2020 as a spinout from the University of Washington and the Altius Institute for Biomedical Sciences, Talus Bio is pioneering a data-enabled drug development platform aimed at revolutionizing oncology treatment through its innovative approach to gene regulation. This latest capital boost will empower the company to accelerate its efforts in developing small-molecule drugs targeting previously undruggable gene regulators in cancers that currently have subpar standard treatment options.
Utilizing a unique platform that allows for the measurement of a drug's capacity to disrupt gene regulators in their natural cellular environment, Talus Bio can analyze the activity of around 1,000 gene regulators concurrently in a single experiment. This advanced technology combines innovative cell processing with high-sensitivity quantitative proteomics and analytics, ensuring precise insights into in-cell drug activity and specificity. With the new funding, Talus Bio plans to advance its internal drug development programs while establishing crucial partnerships with pharmaceutical companies, biotechnology firms, and academic laboratories to enhance their pipelines of gene regulator drugs. This strategic dual approach not only positions Talus Bio as a leader in drug discovery but also highlights its commitment to addressing significant unmet needs in cancer therapy, paving the way for a future where innovative treatments are within reach for patients battling these devastating diseases.
